Although currently there are no approved KIT inhibitors for melanoma, KIT inhibitor imatinib has shown to provide a durable response to a subset of patients with KIT mutant metastatic melanoma with a complete response lasting for more than 1.5 years in a subset of patients [97,98]. The gene discussed is KIT; the disease is metastatic melanoma.